This medication was approved by the FDA in November 2023 for chronic weight management in adults who are obese or overweight with at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol
American College of Cardiology announces late-breaking clinical trials for ACC.26 The latest and greatest in cardiovascular science will be presented during a series of late-breaking, featured clinical research and investigative horizons sessions during ACC.26, the annual meeting of the American College of Cardiology (ACC) in New Orleans
After achieving your desired results, reduce usage to twice a week to maintain the effects
Here are the most practical approaches
Retatrutide is a newer triple-receptor agonist that hits GLP-1, GIP, and glucagon receptors at once, producing fat-loss results that beat anything that came before it
PlexusDx clinicians can evaluate whether a dose reduction, temporary pause, or nutritional intervention is appropriate
